BioAtla (BCAB) Gains from Investment Securities (2024 - 2026)
BioAtla (BCAB) posted quarterly Gains from Investment Securities of -$2.7 million for Q1 2026, down 42.23% year-over-year from -$4.6 million in Q1 2025, and down 221.78% quarter-over-quarter from -$831000.0 in Q4 2025.
BioAtla (BCAB) Gains from Investment Securities (2024 - 2026) Analysis & Trends
BioAtla's Gains from Investment Securities history runs 3 years deep, the most recent figure standing at -$2.7 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 42.23% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at -$1.1 million (up 59.47% YoY), while the FY2025 annual figure was -$295000.0, up 63.44% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$2.7 million, down from -$831000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $2.1 million in Q3 2025, with the low at -$2.7 million in Q1 2026.
- The 3-year median for Gains from Investment Securities is -$819000.0 (2024), against an average of -$629333.3.
- The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities dropped 2.97% in 2025, then slumped 42.23% in 2026.
- BioAtla's Gains from Investment Securities stood at -$807000.0 in 2024, then declined by 2.97% to -$831000.0 in 2025, then slumped by 221.78% to -$2.7 million in 2026.
- Business Quant data shows BCAB's Gains from Investment Securities at -$2.7 million in Q1 2026, -$831000.0 in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -220,000.00 |
| Jun 30, 2026 | -220,000.00 |
| Mar 31, 2026 | -2.67 Mn |
| Mar 31, 2026 | -2.67 Mn |
| Dec 31, 2025 | -831,000.00 |
| Dec 31, 2025 | -831,000.00 |
| Sep 30, 2025 | 2.12 Mn |
| Sep 30, 2025 | 2.12 Mn |
| Jun 30, 2025 | 297,000.00 |
| Jun 30, 2025 | 297,000.00 |
| Mar 31, 2025 | -1.88 Mn |
| Mar 31, 2025 | -1.88 Mn |
| Dec 31, 2024 | -807,000.00 |
| Dec 31, 2024 | -807,000.00 |